ALZAMEND NEURO INC (ALZN) Stock News

USA - Nasdaq - NASDAQ:ALZN - US02262M6057 - Common Stock

2.05 USD

-0.04 (-1.91%)

Last: 12/2/2025, 8:26:23 PM

2.13 USD

+0.08 (+3.9%)

After Hours: 12/2/2025, 8:26:23 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

ALZN Latest News, Press Relases and Analysis

All

Press Releases

13 days ago - By: Zacks Investment Research - Mentions: MEDP EMBC BTSG

EMBC Q4 Preview: Product Momentum and Strategy Gains to Support Growth?

14 days ago - By: Alzamend Neuro, Inc.

Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital

14 days ago - By: Benzinga

EXCLUSIVE: Alzamend Wraps Clinical Phase Of AL001 Study In Healthy Participants

3 months ago - By: Benzinga - Mentions: INSM ADI GES LOW ...

Hewlett Packard Enterprise To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Thursday

4 months ago - By: Alzamend Neuro, Inc.

Alzamend Neuro to Present at the 2025 Military Health System Research Symposium

4 months ago - By: Alzamend Neuro, Inc.

Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs

4 months ago - By: Alzamend Neuro, Inc.

Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs

6 months ago - By: Alzamend Neuro, Inc.

Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule

6 months ago - By: Stocktwits - Mentions: VXF UBER TSLA

Alzamend Neuro Stock Rockets On Dosing Of First Human Patient With Lithium-Delivery System AL001 In Phase II Study: Retail’s Thrilled

6 months ago - By: Alzamend Neuro, Inc.

Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

7 months ago - By: Alzamend Neuro, Inc.

Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

7 months ago - By: Alzamend Neuro, Inc.

Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

7 months ago - By: Yahoo Finance - Mentions: PCLN BKNG EXPE PUBM ...

Booking CFO leans on AI in push to run ‘tight ship’

7 months ago - By: Alzamend Neuro, Inc.

Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital

8 months ago - By: Yahoo Finance - Mentions: GRPN BKNG INTZ

Why Nintendo Stock Is Jumping Today

8 months ago - By: Yahoo Finance - Mentions: COMP

Is Alzamend Neuro, Inc. (ALZN) the Cheapest Stock Insiders Are Buying In March?

8 months ago - By: Alzamend Neuro, Inc.

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer’s Disease to take Place at Massachusetts General Hospital

8 months ago - By: Alzamend Neuro, Inc.

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer’s Disease to take Place at Massachusetts General Hospital

9 months ago - By: Alzamend Neuro, Inc.

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Major Depressive Disorder to take Place at Massachusetts General Hospital

9 months ago - By: Alzamend Neuro, Inc.

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Major Depressive Disorder to take Place at Massachusetts General Hospital

9 months ago - By: Alzamend Neuro, Inc.

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital